Compounded peptide guidance

Lifestyle · Heat 8.2 / 10 · 2 shows · 8m airtime

On October 19, 2026, guidance that would facilitate access to compounded, unapproved peptides reached OMB, and some FDA career staff threatened to resign over it. Kennedy has since put out a plan letting compounding pharmacies and telehealth companies sell six unapproved peptides without FDA review. The guidance remains under review, and the debate touches the agency's broader compounded-drug authority.

How 2 podcasts covered it

1. Squawk Pod, 2026-10-19 (35:15 to 39:58)
   Walks through the compounded-peptide evidence
   Gottlieb walks through the compounded-peptide evidence: an advisory committee saw only 20-to-30-patient series, formulation is inconsistent, and animal data on the Wolverine peptide suggests tumor-promoting vessel growth. He says guidance facilitating access is at OMB and that some FDA career staff threatened to resign.
   New angle: Guidance facilitating access to compounded peptides is at OMB; some FDA career staff threatened to resign over it.
2. What the Health? From KFF Health News, 2026-10-29 (23:19 to 26:24)
   Reports Kennedy's plan to sell six unapproved peptides
   Reports that Kennedy put out a plan on Wednesday letting compounding pharmacies and telehealth companies sell six unapproved peptides without FDA review, bypassing agency safeguards. FDA staff involved opposed it, but the segment frames the move as Kennedy's own, not the OMB guidance.
   New angle: Kennedy put out a plan letting compounding pharmacies and telehealth companies sell six unapproved peptides without FDA review.